146 related articles for article (PubMed ID: 30069671)
1. B7S1, a novel candidate for anti-tumor checkpoint blockade immunotherapy.
Chen X; Ye L
Sci China Life Sci; 2018 Sep; 61(9):1132-1134. PubMed ID: 30069671
[No Abstract] [Full Text] [Related]
2. New checkpoints in cancer immunotherapy.
Ni L; Dong C
Immunol Rev; 2017 Mar; 276(1):52-65. PubMed ID: 28258699
[TBL] [Abstract][Full Text] [Related]
3. Intratumoral CD8
Held W; Siddiqui I; Schaeuble K; Speiser DE
Sci Transl Med; 2019 Oct; 11(515):. PubMed ID: 31645454
[TBL] [Abstract][Full Text] [Related]
4. Potential targeting of B7-H4 for the treatment of cancer.
Podojil JR; Miller SD
Immunol Rev; 2017 Mar; 276(1):40-51. PubMed ID: 28258701
[TBL] [Abstract][Full Text] [Related]
5. The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3.
Janakiram M; Shah UA; Liu W; Zhao A; Schoenberg MP; Zang X
Immunol Rev; 2017 Mar; 276(1):26-39. PubMed ID: 28258693
[TBL] [Abstract][Full Text] [Related]
6. Structure and cancer immunotherapy of the B7 family member B7x.
Jeon H; Vigdorovich V; Garrett-Thomson SC; Janakiram M; Ramagopal UA; Abadi YM; Lee JS; Scandiuzzi L; Ohaegbulam KC; Chinai JM; Zhao R; Yao Y; Mao Y; Sparano JA; Almo SC; Zang X
Cell Rep; 2014 Nov; 9(3):1089-98. PubMed ID: 25437562
[TBL] [Abstract][Full Text] [Related]
7. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.
Dougall WC; Kurtulus S; Smyth MJ; Anderson AC
Immunol Rev; 2017 Mar; 276(1):112-120. PubMed ID: 28258695
[TBL] [Abstract][Full Text] [Related]
8. ADAP and SKAP55 deficiency suppresses PD-1 expression in CD8+ cytotoxic T lymphocytes for enhanced anti-tumor immunotherapy.
Li C; Li W; Xiao J; Jiao S; Teng F; Xue S; Zhang C; Sheng C; Leng Q; Rudd CE; Wei B; Wang H
EMBO Mol Med; 2015 Jun; 7(6):754-69. PubMed ID: 25851535
[TBL] [Abstract][Full Text] [Related]
9. [Cancer immunotherapy by immuno-checkpoint blockade].
Kawakami Y
Rinsho Ketsueki; 2015 Oct; 56(10):2186-94. PubMed ID: 26458459
[TBL] [Abstract][Full Text] [Related]
10. Autocrine Complement Inhibits IL10-Dependent T-cell-Mediated Antitumor Immunity to Promote Tumor Progression.
Wang Y; Sun SN; Liu Q; Yu YY; Guo J; Wang K; Xing BC; Zheng QF; Campa MJ; Patz EF; Li SY; He YW
Cancer Discov; 2016 Sep; 6(9):1022-35. PubMed ID: 27297552
[TBL] [Abstract][Full Text] [Related]
11. The tumour glyco-code as a novel immune checkpoint for immunotherapy.
RodrÍguez E; Schetters STT; van Kooyk Y
Nat Rev Immunol; 2018 Mar; 18(3):204-211. PubMed ID: 29398707
[TBL] [Abstract][Full Text] [Related]
12. Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system.
Pico de Coaña Y; Choudhury A; Kiessling R
Trends Mol Med; 2015 Aug; 21(8):482-91. PubMed ID: 26091825
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges.
Kyi C; Postow MA
Immunotherapy; 2016 Jun; 8(7):821-37. PubMed ID: 27349981
[TBL] [Abstract][Full Text] [Related]
14. Towards In Silico Prediction of the Immune-Checkpoint Blockade Response.
Chen K; Ye H; Lu XJ; Sun B; Liu Q
Trends Pharmacol Sci; 2017 Dec; 38(12):1041-1051. PubMed ID: 29089139
[TBL] [Abstract][Full Text] [Related]
15. The role of neoantigens in response to immune checkpoint blockade.
Riaz N; Morris L; Havel JJ; Makarov V; Desrichard A; Chan TA
Int Immunol; 2016 Aug; 28(8):411-9. PubMed ID: 27048318
[TBL] [Abstract][Full Text] [Related]
16. [Not Available].
Senant M; Giusti D; Weiss L; Dragon-Durey MA
Bull Cancer; 2016 Nov; 103 Suppl 1():S175-S185. PubMed ID: 28057182
[TBL] [Abstract][Full Text] [Related]
17. Part I: Checkpoint inhibitors in cancer therapy.
Daud AI
Immunotherapy; 2016 Jun; 8(6):675-6. PubMed ID: 27197535
[No Abstract] [Full Text] [Related]
18. The path to reactivation of antitumor immunity and checkpoint immunotherapy.
Kim HJ; Cantor H
Cancer Immunol Res; 2014 Oct; 2(10):926-36. PubMed ID: 25281320
[TBL] [Abstract][Full Text] [Related]
19. Neoantigen heterogeneity: a key driver of immune response and sensitivity to immune checkpoint blockade?
Furness AJ; Quezada SA; Peggs KS
Immunotherapy; 2016 Jun; 8(7):763-6. PubMed ID: 27349975
[No Abstract] [Full Text] [Related]
20. Pseudoprogression and hyperprogression after checkpoint blockade.
Wang Q; Gao J; Wu X
Int Immunopharmacol; 2018 May; 58():125-135. PubMed ID: 29579717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]